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bjectives This study sought to estimate the economic impact of same-day home discharge com-
ared with overnight hospitalization after transradial percutaneous coronary intervention (PCI).
ackground Same-day home discharge after transradial PCI and a bolus-only abciximab regimen
as found to be clinically noninferior to the abciximab standard therapy and overnight hospitaliza-
ion in patients with various forms of acute coronary syndromes.
ethods In the EASY (Early Discharge After Transradial Stenting of Coronary Arteries) trial, 1,005
atients were randomized after a bolus of abciximab and uncomplicated transradial coronary stent-
ng, either to same-day home discharge and no infusion (outpatient group) or to overnight hospital-
zation and 12-h abciximab infusion (overnight-stay group). We estimated post-PCI health care cost
in Canadian dollars) of trial subjects and short-term economic impact of same-day home discharge.
s randomization was done after the procedure, outcomes were similar, and PCI resource use
howed minimal and nonsigniﬁcant differences, a post-PCI cost-minimization analysis was con-
ucted. Detailed per-patient information of health care resources used immediately after PCI up to
0 days was collected.
esults Mean post-PCI hospital stay was 8.9 h for outpatients versus 26.5 h for overnight-stay pa-
ients (p  0.001). At 30-day follow-up, the mean cumulative medical cost per outpatient was
1,117  $1,554 versus $2,258  $1,328 for overnight-stay patients. The mean difference of $1,141
95% conﬁdence interval: $962 to $1,320) was mainly due to the extra night for overnight hospital
tay.
onclusions In a real-world setting, same-day home discharge after uncomplicated transradial PCI
nd a bolus-only abciximab regimen resulted in a 50% relative reduction in medical costs. Extension
f this outpatient strategy would be welcomed by the hospitals and reimbursement systems in a
ontext of increasing demand for health care cost reduction. (Early Discharge After Transradial Stent-
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1012npatient treatment of cardiovascular disease remains a
eading cause of increasing health care costs in the indus-
rialized world (1). With an aging population, health care
olicy makers and managers are constantly struggling to
ope with increasing demands for fewer hospital beds. Day
urgery has become the standard of care for many proce-
ures (e.g., cholecystectomy, transurethral prostatectomy)
hat only a few years ago required the patient to stay
ospitalized overnight (2,3). Therefore, any intervention
hat will increase efficiency by reducing hospital length of
tay, especially in cardiac patients, could have a major
See page 1020
mpact on maximizing limited resources. With the advent of
oronary stents and potent antithrombotic drugs such as
lycoprotein IIb/IIIa inhibitors, percutaneous coronary
intervention (PCI) is now an ex-
tremely safe procedure. Nowa-
days, patients who do not experi-
ence periprocedural complications
will usually have an uneventful
in-hospital course (4). Even when
a post-PCI myocardial infarction
(MI) occurs in the absence of an
overt angiographic complication,
long-term mortality for those
patients is not increased when
compared with long-term mor-
tality of patients without post-
PCI MI (5). In addition, with
the use of the transradial ap-
proach, catheter site bleeding
complications are now extremely
infrequent (6). Therefore, the
need for the routine overnight
hospital stay following PCI has
een questioned. In the large single-center EASY (Early
ischarge After Transradial Stenting of Coronary Arteries)
rial, same-day home discharge after uncomplicated trans-
adial PCI and a bolus-only abciximab regimen was found
o be clinically noninferior to the abciximab bolus and 12-h
nfusion standard therapy and overnight hospitalization in
atients with various forms of acute coronary syndromes (4).
ame-day discharge after elective PCI via the femoral
pproach was also reported to be feasible and safe in the
ajority of patients selected for day-case PCI (7). Further-
ore, a recent observational study also reported the safety
nd feasibility for a prospective evaluation of ambulatory
ransradial PCI in an American practice setting (8).
Resources freed due to such an outpatient strategy could
e redirected to more valuable and cost-effective purposes.
bbreviations
nd Acronyms
HUM  Centre Hospitalier
e l’Université de Montréal
RG  diagnostic-related
rouping
UCPQ  Institut
niversitaire de Cardiologie
t de Pneumologie de
uébec
I  myocardial infarction
IRRU  Niveau d’Intensité
elative des Ressources
tilisées
CI  percutaneous
oronary intervention
AMQ  Régie de
’Assurance Maladie
u Québececause in the EASY trial clinical outcomes (including teath, MI, urgent revascularization, major bleeding, repeat
ospitalization, access site complications, and severe throm-
ocytopenia) were similar at 30 days (4), the purpose of our
tudy was to estimate the cost difference between the 2
reatment approaches (cost-minimization analysis) using
icrocosting and macrocosting analysis.
ethods
linical trial. The details of the EASY trial have been
reviously described (4). Briefly, patients referred for coro-
ary angiography and possible PCI were enrolled from
ctober 2003 to April 2005 at the Institut Universitaire de
ardiologie et de Pneumologie de Québec (IUCPQ), (for-
erly Laval Hospital). Patients were excluded if they
resented with ST-segment elevation MI within 72 h or
ad previous left ventricular ejection fraction30%. Except
or a secondary branch in a bifurcation lesion or repeat
ilation for in-stent restenosis, all severe lesions had to be
tented. The protocol was approved by Health Canada and
he IUCPQ Ethics Review Board. All patients signed
nformed consent forms for participation in the trial.
The study was a randomized, controlled, open-label study
omparing same-day home discharge and abciximab bolus
nly (outpatient group, n  504) to overnight hospitaliza-
ion and bolus followed by 12 h of abciximab infusion
hospitalized group, n 501) after uncomplicated transradial
oronary stenting. In case of suboptimal results or clinical
omplications during the PCI procedure, patients were ex-
luded from randomization and received abciximab bolus and
nfusion. Abciximab was administered as a 0.25-mg/kg bolus
efore first balloon angioplasty, and infusion was given for a
otal of 12 h at 0.125 g/kg/min to a maximum of 10 g/min.
ll patients received aspirin and clopidogrel before diagnostic
ngiography. After radial or ulnar sheath insertion, a bolus of
0 U/kg heparin was given intravenously. Vascular sheaths
ere removed at the end of the procedure, and a bracelet
Hemostop, Zoom, Inc., Piedmont, Quebec) remained in
lace until hemostasis was completed. Primary end point at 30
ays was a composite of death, MI, urgent revascularization,
ajor bleeding, repeat hospitalization, access site complication,
nd severe thrombocytopenia.
ummary of economic methods. Detailed per-patient re-
ources used were collected prospectively in case-report
orms as planned at the beginning of the study. Given that
he IUCPQ billing services were not at the time of the study
easuring per-patient costs in their different services and
epartment, we relied on a similar Canadian hospital
Centre Hospitalier de l’Université de Montréal or CHUM)
etailed costing system for the unit costs used in our
icrocosting approach. Finally, we assessed the impact ofhe costing strategy on our results by using other sources of
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1013osts (macrocosting). We used a time horizon of 30 days
fter PCI, when the primary end point was measured.
esources measurements. Detailed per-patient information
as recorded in dedicated case-report forms with respect to
he procedural resources used, procedural complications,
nd hospital admission and discharge dates for all patients
n the trial. The exact moment of completion of the
ntervention and discharge after the PCI was recorded, and
he duration of post-PCI hospitalization was calculated for
ll subjects. All patients were evaluated, either through
irect patient contact or by telephone, within 4 to 6 h, 24 h,
nd 30 days of the procedure, and detailed information was
ecorded with respect to subsequent angiogram or PCI
inpatient or outpatient), related surgery, repeat and pro-
onged hospitalizations, prescription drugs used, tests per-
ormed, and unscheduled physician visits. When possible,
he diagnostic-related grouping (DRG) assigned by the
ospital archiving system was retrieved for both the initial
ospitalization associated with the PCI and for repeat
ospitalizations within 30 days.
osts. As the subjects were randomized following PCI, the
osts of resources used were estimated beginning immedi-
tely after the procedure. Therefore, costs following PCI,
ncluding costs during the index hospitalization and after
ischarge up to 30 days after PCI, were measured. Costs
ere calculated from the perspective of the institution using
nly hospital-based costs and also from the perspective of
he health care system by adding the hospital-based costs,
hysician fees, and prescription drug costs for a modified
edical system perspective.
Hospitalization costs were computed spanning the time
rom randomization up to 30 days after the procedure and
ncluded in-hospital drug use, any repeat cardiovascular
rocedures (angiogram or PCI), urgent revascularization,
mergency department visits, nonscheduled outpatient
linic visits, and subsequent hospitalizations. Patients dis-
harged home the same day were requested to complete an
utpatient blood test and were called the following day by a
urse. These costs were included in the total cost calcula-
ion. The costs of inpatient resources used (e.g., nursing
ime, medication, procedures, and overhead) were based on
costing system developed at CHUM (9). Briefly, it
dentifies precisely the utilization of hospital-based services
or any given patient, for any DRG, and at any given
ospital visit (outpatient, emergency department, inpatient
tay).
Hourly cost of post-PCI hospitalization was estimated at
65/h, based on the mean 2005 to 2006 cost for patients
ospitalized with DRG 112 (levels 1 to 3) with angioplasty
nd stent ($5,716), subtracting the estimated cost of the
CI procedure itself ($3,078), and dividing the remaining
osts by the mean length of stay of patients in the hospi-
alized group. cTo estimate costs of rehospitalizations within 30 days,
rice per episode was approximated using the complexity-
ased DRG, a classification method that groups hospital-
zation episodes by center and type of expenses using
ollected and reported financial and statistical data for each
vent. It takes into account direct inpatient costs, allocated
verhead, diagnostic and therapeutic services, and excludes
hysician compensation, capital costs for buildings and
ermination benefits or pre-retirement leave for personnel.
ases are classified according to diagnosis, procedures, age,
nd complexity. Within a group, typical cases are all
ssigned a same resource-intensity weight, whereas atypical
ases (e.g., deaths, transfers) are assigned a unique and
pecific resource-intensity weight according to the length of
tay. The DRG of each hospitalization at IUCPQ was
etrieved as coded for the index hospitalization. When
navailable (generally for patients hospitalized in other
enters), the most likely DRG for the hospitalization was
elected based on the detailed information collected in the
ase-report forms. Similar methodology has been used in
ther studies (10).
Cost associated with glycoprotein IIb/IIIa inhibitor ab-
iximab at index intervention included only the infusion cost
s the bolus was mandatory in both treatment groups.
The cost of major follow-up outpatient procedures (cor-
nary angiograms or PCI) were estimated according to a
etailed, per-procedure microcosting evaluation of each
rocedure based on the CHUM catheterization laboratory
ystem cost for the year 2002 to 2003 and revised using the
onsumer price index for health care from 2002 to 2006, to
stimate the 2006 costs (11). This microcosting system
ncludes staff costs, overhead costs for the laboratory, and
asic material for coronary angiography and PCI.
In addition to the costs of hospitalizations and hospital-
ased procedures, our analysis also included costs for phy-
ician services (as normally billed to the provincial health
rogram) and prescription drug use (net of beneficiary
opayment). The usual number and type of in-hospital
hysician services were estimated for patients in the 2
roups. They included 2 visits by the interventional cardi-
logist for the overnight stay group versus 1 for outpatients.
similar approach was applied for subsequent procedures
ncluding repeat coronary angiography and PCI procedures.
osts of unscheduled outpatient visits related to cardiovas-
ular care were also included in our analysis, with costs for
ach service based on the 2007 Régie de l’Assurance
aladie du Québec (RAMQ) fee schedule, the unique
ublic payer in the province (Table 1) (12).
Outpatient prescription drugs use was recorded for 10
ardiac drug classes at each visit. For each medication class,
e assigned an average 30-day cost based on data from the
AMQ drug reimbursement program. Specifically, we
ompared the average daily prescription drugs in these
lasses to a similar sample of beneficiaries of the RAMQ
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1014rovincial drug program and were able to estimate the cost
f prescription drug use per patient for the 30 days following
he procedure, while excluding the drugs administered
uring hospitalization (12). Details of these costs are also
ound in Table 1.
ensitivity analyses. Sensitivity analyses were conducted on
ey assumptions in order to consider alternative costs of key
esources where alternative data were available. The 2002 to
003 Niveau d’Intensité Relative des Ressources Utilisées
NIRRU) (the Quebec weighting factor derived for the case
ix group) average cost of diagnostic-related groups 111
nd 112 (PCI) levels 1 to 3 (weighted by the number of
Table 1. Unit Costs per Patient for Economic Analysis
Resource $CDN Sen
In-patient resource use
Post-procedure hospital hourly cost $65
Abxicimab 10-mg vial $111
Subsequent procedures or visits (outpatient)
Basic outpatient visit $23
Coronary angiography (uncomplicated) $1,847 $
PCI $3,078
Emergency department visit $224
Repeat hospitalization DRG§ Per DRG§
Prescribed outpatient drugs (per day cost)
Aspirin $0.19
Statins $1.40
Other lipid-lowering agents $1.18
ACE inhibitor $0.79
Beta-blocker $0.34
Calcium-channel blocker $1.08
Clopidogrel $1.95
Angiotensin II antagonists $0.85
Nitrates $0.68
Warfarin $0.34
Physician fees
Total physician fees for outpatient angiogram $655
Total physician fees for PCI $786
Cardiologist ofﬁce visit $50
Cardiologist inpatient control visit $23
Cardiologist outpatient control visit $17
Emergency department visit $79
Physician (general practitioner) ofﬁce visit $63
Follow-up call for intervention subjects
Nursing time for phone call (10 min) $4.54
Laboratory blood test (complete blood test and CK-MB) $2.95
Amounts $10 are rounded to nearest dollar. *Lower limit tested. †NIRRU Quebec 2002–2003 (in
hospitalization episode.
ACE  angiotensin-converting enzyme; CDN  Canadian; CHUM  Centre Hospitalier de
DRG  diagnostic-related group; IMS  Intercontinental Marketing Services; NIRRU  Niveau d’In
l’Assurance Maladie du Québec.ases in each group) and inflated by the consumer price sndex of 7.3% was estimated to be $6,658. This figure was
sed to estimate an alternative hourly cost for post-PCI stay
$88). Additionally, the province of Alberta’s 2004 to 2005
verage cost of case mix groups 188 and 189 (PCI) levels 1
o 3 (weighted by the number of cases in each group) was
stimated to be $9,820. We used this figure to estimate an
lternative hourly cost for post-PCI stay ($167). A 2002 to
003 NIRRU for outpatient angiogram and the average
utpatient procedure cost (NIRRU  1) of $441 (2002 to
003) increased by the consumer price index of 7.3%
$473) and the Alberta 2004 to 2005 outpatient cost for
ngiogram of $2,048 were also used to test the impact of
y Analyses Source
10*
88†
167‡
CHUM 2005–2006
2007 IMS Health Canada, Canadian drugstores, and hospital
purchases audit
CHUM 2005–2006
$2,048‡ CHUM 2002 detailed costing (increased by CPI of 7.3%)
CHUM 2002 detailed costing (increased by CPI of 7.3%)
CHUM 2005–2006
056† CHUM 2005–2006
Average daily cost to provincial program from 2004/2005 RAMQ
drug program beneﬁciaries (increased by CPI of 3.4%)
2007 RAMQ manuals for specialists and for general practitioners
1/6 of average nursing visit cost of $26.34 (10) increased by 3.4%
Laboratoire de biologie medicale, mesure de la production ed.
2006–2997, Sante et services sociaux Quebec
by CPI of 7.3%). ‡Alberta 2004–2005. §DRG is classified according to complexity level for each
rsité de Montréal; CK-MB  creatine kinase-myocardial band; CPI  consumer price index;
Relative des Ressources Utilisées; PCI  percutaneous coronary intervention; RAMQ  Régie desitivit
$
$
$
473† to
$4,
creased
l’Unive
tensitéubsequent outpatient angiograms. To test the impact of
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1015ehospitalization costs, we used the average short dura-
ion hospitalization cost of $3,780 in Quebec in 2002 to
003 and adjusted it again for 2006 by 7.3% ($4,056).
inally, the impact of the abciximab infusion cost was
ssessed.
ata analyses. Data are presented as percentage, mean with
tandard deviation or 95% confidence intervals (CI) and
edians with interquartile (25th to 75th percentile) range
IQR). Proportions were compared using chi-square test,
nd given the large sample size, continuous data were
ompared with 2-sample t test irrespective of the distribu-
ion of the data, unless specified (13). Average per-patient
ost components and aggregated costs of health services use
ithin 30 days after PCI were calculated by summing all
vailable costs from all patients and dividing by the number
f patients contributing for that component. Costs are
xpressed as 2006 Canadian dollars. Given the short-term
erspective of the analysis, no discounting was performed.
nalyses were performed with SPSS statistics software
ersion 16.0.1 (SPSS, Inc., Chicago, Illinois).
esults
er-procedure resource use. Resource utilization for the
ndex PCI procedure is summarized in Table 2. There were
Table 2. Resource Use During the Index PCI Procedure
(Prior to Randomization)
Resources Used
Same-Day Home
Discharge
(n  504)
Overnight Stay
(n  501) p Value
Number of stents implanted 0.16
0, % 0.2 1.2
1, % 60.3 58.7
2, % 30.0 27.9
3, % 6.5 9.4
4 or more, % 3 2.8
Drug-eluting stents, % 18 18 0.89
Angiography and PCI equipment,
n per case
Diagnostic catheter(s) 1.7 0.74
2 [1–2]
1.69 0.78
2 [1–2]
0.77
Guiding catheter(s) 1.27 0.69
1 [1–1]
1.27 0.55
1 [1–1]
0.99
Guidewire(s) 1.45 0.89
1 [1–2]
1.42 0.83
1 [1–2]
0.64
Balloon(s) 1.99 1.68
2 [1–3]
2.01 1.63
2 [1–3]
0.86
Stent(s) 1.52 0.78
1 [1–2]
1.54 0.81
1 [1–2]
0.73
Contrast media, ml 201 76
190 [150–230]
197 72
190 [150–230]
0.46
Abciximab bolus, mg 20 4
20 [18–22]
20 4
20 [17–22]
0.69
Data are presented as mean SD and median [ 25th to 75th percentile], or percentagepwhen indicated.o significant differences in the angiography or PCI equip-
ent or number of stents used between outpatient group
nd overnight hospitalized group.
n-hospital resource use. As expected and per protocol, the
ean post-PCI hospital length of stay was longer in
atients hospitalized overnight (26.5  14.3 h; median:
2.9 h, IQR: 20.8 to 24.9 h) than for outpatients (8.9 
.5 h; median: 6.7 h, IQR: 5.8 to 8.4 h) (p  0.001), for a
ean difference of 17.7 h (95% CI: 16.3 h to 19.1 h).
ollow-up resource use. Fifty-one repeat hospitalizations
or any cause, related or not to the index procedure, occurred
ithin 30 days of the index PCI, in 29 outpatients and in 21
atients in the overnight stay group (p  0.26). Mean and
edian length of stay for these rehospitalized subjects was
.28 and 2 days in the early discharge group versus 3.81 and
days in the overnight stay group (Wilcoxon rank-sum p
.51). One outpatient was rehospitalized twice. Index
rocedure-related repeat hospitalizations were noted in 24
utpatients and 17 overnight stay patients (p  0.27).
ithin the same period, subsequent angiograms were per-
ormed in 10 outpatients and in 7 overnight stay patients
p  0.47), and repeat PCI was performed in 5 outpatients
ersus none in the overnight stay group (p  0.025). There
as no significant difference in the number of reported
nscheduled physician visits between the 2 groups (0.11 per
atient for both groups; p  0.89).
osts. At 30-day follow-up, and from the perspective of the
nstitution, the total hospital-based costs incurred by an
utpatient were estimated to be $891  $1,434 (median:
459, IQR: $391 to $611) compared with $2,018  $1,280
median: $1,618, IQR: $1,492 to $1,788) per patient in the
vernight stay group (p  0.001) for a difference of $1,127
95% CI: $959 to $1,296) (Figs. 1 and 2). The mean
umulative health care costs per patient were estimated to be
1,117 $1,554 (median: $667, IQR: $580 to $822) in the
utpatient group compared with $2,258  $1,328 (median:
1,851, IQR: $1,709 to $2,015) in the overnight stay group
p  0.001). The $1,141 per patient (95% CI: $962 to
1,320) difference in cost was due mainly to the reduction in
ost related to the extra night for post-PCI overnight stay,
s there were no significant differences in follow-up costs for
rocedures, physician services, or medications.
ensitivity analyses. The base case analysis estimated a
1,127 difference in total hospital-based costs. Increasing
he estimated hourly hospitalization cost only increased this
ifference between the groups. Reducing the cost decreased
he difference, but the balance favored the outpatient group
ven when reducing the cost as low as $10 per hour. As
rchive-coded hospitalization types were available for only a
ubset (n  21) of the subjects’ rehospitalization episodes
mainly for those occurrences at the IUCPQ), we examined
his subset of subjects by comparing their estimated rehos-
italization costs to the subjects for whom a DRG had been
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1016ssigned, and little difference was observed. Even if all
ubjects with created and assigned DRG were removed, the
nalyses yielded results similar to the base case analysis.
eplacing the DRG-specific hospitalization costs with the
verage NIRRU-based cost had little impact on the results
Table 3).
iscussion
e found that a strategy of same-day home discharge
ollowing uncomplicated transradial PCI saved on aver-
Figure 1. Average Per-Patient Cost Components of Health Services Use W
When no p value is indicated, p  0.05. PCI  percutaneous coronary intervenge $1,141 per patient compared with the post-PCI bvernight stay strategy, without any harm to the patients.
uch an amount represents a 50% relative saving in
ost-PCI costs. For every 1,000 outpatients, such strat-
gy could yield over $1 million in savings. Such savings
ere achieved with trivial system costs of implementing
he early discharge program, essentially nursing time cost
f $7 per patient. Finally, we found little evidence of
ncreased resource utilization or cost during the 30-day
ollow-up period.
Few post-intervention strategies in health care actually
ave costs. Hence, our findings have important implications,
0 Days Post-PCIithin 3oth from the institution and the health care system
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1017erspective. In-patient treatment of cardiovascular disease
till represents a substantial amount of all health care
esources spent in the industrialized world. In 2006, $43.9
Figure 2. Cumulative Health Care Costs Within 30 Days
Post-Percutaneous Coronary Intervention
CI  conﬁdence interval.
Table 3. Sensitivity Analyses: Results of Varying Significant Cost Items an
Cost Item Value Varied
Same-Day Home Discharge
(n  504)
Mean  SD
Median [IQR]
Post-stay hourly cost
Base case, $65/h $891  $1,434
$459 [$391–$611]
Increase to $167/h $1,792 $1,902
$1,154 [$986–$1,508]
Increase to $88/h $1,093  $1,518
$616 [$525–$807]
Decrease to $10/h $403  $1,305
$77 [$66–$103]
Rehospitalization cost
Use NIRRU cost of $4,056 $886  $1,320
$459 [$391–$611]
Remove cost of infusion $890 $1,434
$459 [$391–$611]
Remove subjects with DRG created for
rehospitalization
$736  $1,177
$455 [$389–$583]IQR interquartile range (25th to 75th percentile); other abbreviations as in Table 1.illion was spent in the U.S. on hospital admissions for
eart ailments (1). As shown, most of the savings were
erived by shortening of the hospital stay, and avoidance of
he abciximab infusion, although savings would still be
resent even when ignoring abciximab infusion costs.
herefore, with other periprocedural antithrombotic strat-
gies, such as with bivalirudin, which can be stopped
mmediately after the procedure (14,15), hospital savings of
1,127 per patient would be expected in cases of uncompli-
ated PCI. Moreover, from the health care system perspec-
ive, the fact that hospital savings were not offset by
ollow-up increase in health care resources consumption is
eassuring.
It would be tempting to perceive this strategy as poten-
ially unprofitable for U.S. hospitals; however, 62% of the
atients were already hospitalized for an acute coronary
yndrome. Given that reimbursement is not dependent on
ength of stay in U.S. hospitals but rather on assigned DRG
y Medicare or private insurers, we believe that adopting a
ame-day discharge strategy for acute coronary patients
ould lead to profit for individual hospitals implementing it.
reatment of coronary artery diseases still represents a
ignificant cost burden to U.S. society, with almost 1.2
illion hospital discharges in the U.S. alone in 2006 (16).
here is also a major move in the U.S. to pay hospitals
utpatient rates for elective, uncomplicated PCI, and these
ayments are about 50% of those for inpatient PCI. There-
ore, U.S. hospitals should have tremendous incentive to
dentify cost savings for the PCI programs. Recently, Jabara
t al. (8) reported the safety and feasibility for a prospective
valuation of ambulatory transradial PCI in an American
ractice setting.
act on Estimated Hospital-Based Costs
Overnight Stay
(n  501)
Mean  SD
Median [IQR] Mean Difference (95% CI) p Value
$2,018  $1,280
$1,618 [$1,492–$1,788]
–$1,127 (–$959 to –$1,296) 0.001
$4,719 $2,554
$3,960 [$3,628–$4,405]
–$2,927 (–$2,649 to –$3,206) 0.001
$2,623  $1,537
$2,141 [$1,973–$2,374]
–$1,556 (–$1,431 to –$1,680) 0.001
$554  $878
$344 [$323–$376]
–$152 (–$14 to –$289) 0.031
$2,036  $1,325
$1,618 [$1,492–$1,788]
–$1,151 (–$987 to –$1,314) 0.001
$1,908  $1,280
$1,507 [$1,383–$1,677]
–$1,018 (–$849 to –$1,186) 0.001
$1,917  $1,047
$1,614 [$1,491–$1,767]
–$1,180 (–1,041 to –$1,320) 0.001d Imp
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1018Early discharge after elective PCI via the femoral ap-
roach was also reported to be feasible and safe in a majority
f patients selected for day-case PCI, despite a higher risk of
leeding related to the transfemoral procedure (6,7). How-
ver, cost savings related to such early discharge strategy
ere less than 10%. Only a minority of U.S. operators have
dopted the transradial route for routine catheterization and
CI (16). The transradial route, although technically more
emanding at beginning, can be used routinely by most
perators within a very short learning period. Besides, the
ery low bleeding rates associated with the transradial
pproach allow operators to use whichever peri-PCI anti-
hrombotic regimen, without increased risks (6). Recent
arge trials have tested new drugs to reduce the risk of
leeding after PCI (14,15), bleeding that in turn greatly
ncreases the risk of long-term mortality, as much as an MI
17). However, the transradial route almost completely
educes site-related bleeding. Economic savings from same-
ay home discharge following transradial approach may
ncourage a larger uptake of this site access in the near
uture.
tudy limitations. First, hospital payments in Canada are
ot based on individual charges but rather on fixed budgets.
s few hospitals collect individual per-patient costs for
anagement purposes, we based our post-PCI hourly unit
osting, the major cost driver of our analysis, on costs
erived from similar cases treated at CHUM. It is possible
hat some of the cost items included in the post-PCI
ospital cost (e.g., nursing, meals) differ slightly at the
UCPQ where the study was performed. However, both
nstitutions are large Canadian teaching hospitals, located in
he same province, and have an overall similar administra-
ive and clinical structure. Moreover, when using a coarser
osting method such as the NIRRU method, estimates of
avings remain substantial and for the most part unchanged.
econd, we only used a case-mix–based costing model for
ollow-up hospitalizations. Because these costs represented
20% of the full 30-day costs, it is unlikely that a more
recise estimate would have changed the magnitude of our
ndings. Furthermore, our analysis does not take into
onsideration the potential disutility or inconvenience asso-
iated with the outpatient blood sample performed in
atients discharged the same day. Neither does it consider,
n the other hand, the potential advantage and preference of
eing home the night after the PCI. It would be extremely
nlikely that such short-term utility differences, if present,
ould offset the substantial savings observed. Given that
ajor health care outcomes were similar, we felt that a
ost-minimization approach was reasonable. Fourth, we did
ot measure individual patient medications by item but
ather by class, but medication cost is not a major cost driver
n our analysis. Fifth, we measured cost up to 30 days, when
he primary end point was assessed. Given the lack of
ifferences in clinical outcomes, it would seem unlikely thathere would be systematic differences in health care resource
tilization or attendant costs in a longer-term analysis.
ixth, as repeat PCI was performed in 5 outpatients versus
one in the overnight stay group (p  0.025), one could
rgue that a cost-minimization analysis was not justified.
owever, the study clearly reported similar primary out-
omes rates at 30 days, so we felt justified to limit the
nalysis to costs. Moreover, the significant difference in
epeat revascularization at 30 days is likely a chance effect.
espite including those repeat revascularization costs in the
nalysis, aggregated costs were still lower with early dis-
harge. Seventh, repeat hospitalization and procedure-
elated hospitalization event rates are low in absolute num-
ers, resulting in low power for these comparisons. Eighth,
he applicability of these findings from a public medical
ystem to that of the U.S. needs to be confirmed. Finally,
ur result may only apply to patients treated from a
ransradial approach.
onclusions
here is substantial economic incentive for same-day home
ischarge of patients following an uncomplicated transradial
CI, even in patients admitted for an acute coronary
yndrome as in the EASY trial. Savings in health care
pending may be turned into profit in specific situations,
hen in-patient treatment of acute coronary treatment can
e safely abrogated.
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